Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYunfei HuYHYunhong Huang

Discussion

Loading...

Member takes

Overview

Retrospective study shows high efficacy and safety of orelabrutinib regimens in marginal zone lymphoma, indicating potential for improved patient outcomes.

Key Points

  • To explore the efficacy and safety of orelabrutinib-based regimens for treating marginal zone lymphoma in a real-world setting.
  • Retrospective study including patients receiving orelabrutinib induction therapy
  • Outcomes measured: overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and safety
  • Included a cohort of 57 patients at Guizhou Provincial Cancer Hospital, China.
  • Overall response rate (ORR) of 84.0% among efficacy-evaluable patients
  • Complete response (CR) rate of 50.0%, with disease control rate (DCR) at 98.0%
  • 12-month PFS rate of 94.2%, indicating durable outcomes.

Cite This Study

Hu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d45ahttps://doi.org/10.1182/blood-2025-1817
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  2. 2Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.2026
  3. 3Orelabrutinib with anti-CD20 monoclonal antibodies is highly effective and well-tolerated as first-line therapy for marginal zone lymphoma2026 · 1 citations
  4. 4Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  5. 5Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study2025